{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:23:49Z","timestamp":1784755429644,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,8,5]]},"DOI":"10.1007\/s12185-019-02683-1","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T02:02:27Z","timestamp":1560132147000},"page":"187-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy"],"prefix":"10.1007","volume":"110","clinical-trial-number":[{"clinical-trial-number":"nct02148133","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3018-2098","authenticated-orcid":false,"given":"Hirohito","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Imada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Obara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Tokumine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Imajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Fanghong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"key":"2683_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12185-013-1352-6","volume":"98","author":"DM Townsley","year":"2013","unstructured":"Townsley DM, Desmond R, Dunbar CE, Young NS. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. Int J Hematol. 2013;98:48\u201355.","journal-title":"Int J Hematol"},{"key":"2683_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1053\/j.seminhematol.2014.10.002","volume":"52","author":"R Desmond","year":"2015","unstructured":"Desmond R, Townsley DM, Dunbar C, Young NS. Eltrombopag in aplastic anemia. Semin Hematol. 2015;52:31\u20137.","journal-title":"Semin Hematol"},{"key":"2683_CR3","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.2147\/DDDT.S95715","volume":"10","author":"SH Lum","year":"2016","unstructured":"Lum SH, Grainger JD. Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Des Dev Ther. 2016;10:2833\u201343.","journal-title":"Drug Des Dev Ther"},{"key":"2683_CR4","doi-asserted-by":"publisher","first-page":"i178","DOI":"10.1093\/ije\/dyv096.259","volume":"44","author":"A Ohta","year":"2015","unstructured":"Ohta A, Nagai M, Nishina M, Shimada N, Nakao S, Kurokawa M. Incidence of aplastic anemia in Japan: analysis of data from a nationwide registration system. Int J Epidemiol. 2015;44:i178.","journal-title":"Int J Epidemiol"},{"key":"2683_CR5","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","volume":"129","author":"A Bacigalupo","year":"2017","unstructured":"Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129:1428\u201336.","journal-title":"Blood"},{"key":"2683_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12185-009-0302-9","volume":"89","author":"N Nishio","year":"2009","unstructured":"Nishio N, Yagasaki H, Takahashi Y, Muramatsu H, Hama A, Yoshida N, et al. Natural history of transfusion-independent non-severe aplastic anemia in children. Int J Hematol. 2009;89:409\u201313.","journal-title":"Int J Hematol"},{"key":"2683_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3324\/haematol.10075","volume":"92","author":"A Locasciulli","year":"2007","unstructured":"Locasciulli A, Oneto R, Bacigalupo A, Soci\u00e9 G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European group for blood and marrow transplantation (EBMT). Haematologica. 2007;92:11\u20138.","journal-title":"Haematologica"},{"key":"2683_CR8","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1182\/blood-2013-05-498279","volume":"122","author":"JCW Marsh","year":"2013","unstructured":"Marsh JCW, Kulasekararaj AG. Management of the refractory aplastic anemia patient: what are the options? Blood. 2013;122:3561\u20137.","journal-title":"Blood"},{"key":"2683_CR9","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.leukres.2010.02.005","volume":"34","author":"CL Erickson-Miller","year":"2010","unstructured":"Erickson-Miller CL, Kirchner J, Aivado M, May R, Payne P, Chadderton A. Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res. 2010;34:1224\u201331.","journal-title":"Leuk Res"},{"key":"2683_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.scr.2012.05.001","volume":"9","author":"H Sun","year":"2012","unstructured":"Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem\/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012;9:77\u201386.","journal-title":"Stem Cell Res"},{"key":"2683_CR11","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","volume":"123","author":"R Desmond","year":"2014","unstructured":"Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123:1818\u201325.","journal-title":"Blood"},{"key":"2683_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3999\/jscpt.42.11","volume":"42","author":"Y Shida","year":"2011","unstructured":"Shida Y, Takahashi N, Nohda S, Hirama T. Pharmacokinetics and pharmacodynamics of eltrombopag in healthy Japanese males. Jpn J Clin Pharmacol Ther. 2011;42:11\u201320.","journal-title":"Jpn J Clin Pharmacol Ther"},{"key":"2683_CR13","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1177\/0091270010375427","volume":"51","author":"E Gibiansky","year":"2011","unstructured":"Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2011;51:842\u201356.","journal-title":"J Clin Pharmacol"},{"key":"2683_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1200931","volume":"367","author":"MJ Olnes","year":"2012","unstructured":"Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11\u20139.","journal-title":"N Engl J Med"},{"key":"2683_CR15","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1182\/blood-2007-01-066258","volume":"110","author":"EE Solomou","year":"2007","unstructured":"Solomou EE, Rezvani K, Mielke S, Malide D, Keyvanfar K, Visconte V, et al. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood. 2007;110:1603\u20136.","journal-title":"Blood"},{"key":"2683_CR16","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood-2011-08-368308","volume":"119","author":"S Kordasti","year":"2012","unstructured":"Kordasti S, Marsh J, Al-Khan S, Jiang J, Smith A, Mohamedali A, et al. Functional characterization of CD4+ T cells in aplastic anemia. Blood. 2012;119:2033\u201343.","journal-title":"Blood"},{"key":"2683_CR17","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1182\/blood-2011-11-390708","volume":"120","author":"J Shi","year":"2012","unstructured":"Shi J, Ge M, Lu S, Li X, Shao Y, Huang J, et al. Intrinsic impairment of CD4(+) CD25(+) regulatory T cells in acquired aplastic anemia. Blood. 2012;120:1624\u201332.","journal-title":"Blood"},{"key":"2683_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00277-016-2629-7","volume":"95","author":"AT Dao","year":"2016","unstructured":"Dao AT, Yamazaki H, Takamatsu H, Sugimori C, Katagiri T, Maruyama H, et al. Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia. Ann Hematol. 2016;95:771\u201381.","journal-title":"Ann Hematol"},{"key":"2683_CR19","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","volume":"116","author":"W Bao","year":"2010","unstructured":"Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116:4639\u201345.","journal-title":"Blood"},{"key":"2683_CR20","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood.V128.22.3870.3870","volume":"128","author":"H Cheng","year":"2016","unstructured":"Cheng H, Cheruku PS, Alvarado L, Cash A, Dunbar CE, Young NS, et al. Interferon-\u03b3 perturbs key signaling pathways induced by thrombopoietin, but not eltrombopag, in human hematopoietic stem\/progenitor cells. Blood. 2016;128:3870.","journal-title":"Blood"},{"key":"2683_CR21","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1016\/S2352-3026(15)00149-0","volume":"2","author":"U Platzbecker","year":"2015","unstructured":"Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1\/2 trial. Lancet Haematol. 2015;2:e417\u201326.","journal-title":"Lancet Haematol"},{"key":"2683_CR22","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2352-3026(17)30012-1","volume":"4","author":"EN Oliva","year":"2017","unstructured":"Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017;4:e127\u201336.","journal-title":"Lancet Haematol"},{"key":"2683_CR23","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1182\/blood-2018-06-855221","volume":"132","author":"M Dickinson","year":"2018","unstructured":"Dickinson M, Cherif H, Fenaux P, et al. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018;132:2629\u201338.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02683-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-019-02683-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02683-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:09:34Z","timestamp":1628597374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-019-02683-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8,5]]}},"alternative-id":["2683"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02683-1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735972916.793577876","asserted-by":"object"}]},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"2 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HY has received grant\/personal fees\/non-financial support from Novartis. KO has received personal fees from Takeda, Celgene, Janssen, Bristol-Meyers Squibb, Ono, and Novartis. KI have received personal fees from Novartis, Bristol-Meyers Squibb, Takeda, Celgene, Nippon Shinyaku, MSD, Chugai, and Sumitomo Dainippon. YT received personal fees Novartis, Kyowa Hakko Kirin, and Chugai and provided advisory role to Novartis and Sysmex. HI, KM, and NO have declared no conflict of interest. KU has received grants from Astellas, AbbVie, Alexion, Gilead Sciences, SimBio, Daiichi-Sankyo, Sumitomo Dainippon, and personal fees from Novartis. TH, TT, and ZF are employees of Novartis. AM received personal fees from GlaxoSmithKline and Novartis Pharma during the conduct of the study, grants, and personal fees from Chugai, Kyowa Hakko Kirin, Sumitomo Dainippon, Nippon Shinyaku, GlaxoSmithKline, Novartis, Celgene, Alexion, Sanofi and Beckman Coulter, Shire Japan KK, Astellas, Asahi Kasei, Eisai, Otsuka, Boehringer Ingelheim, MSD, Daiichi-Sankyo, Abbvie, and HUYA Bioscience. SN has received personal fees from Novartis and Alexion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}